"Erythropoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
| Descriptor ID |
D004921
|
| MeSH Number(s) |
D12.644.276.374.410.240.150 D12.776.395.240.150 D12.776.467.374.410.240.150 D23.529.374.410.240.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erythropoietin".
Below are MeSH descriptors whose meaning is more specific than "Erythropoietin".
This graph shows the total number of publications written about "Erythropoietin" by people in this website by year, and whether "Erythropoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2003 | 1 | 3 | 4 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 8 | 2 | 10 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 2 | 4 |
| 2011 | 4 | 0 | 4 |
| 2012 | 4 | 1 | 5 |
| 2013 | 3 | 1 | 4 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 0 | 2 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 4 | 3 | 7 |
| 2022 | 5 | 1 | 6 |
| 2023 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erythropoietin" by people in Profiles.
-
Hypothermia and erythropoietin for neuroprotection after neonatal brain damage. Pediatr Res. 2013 Jan; 73(1):18-23.
-
Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock. J Neurotrauma. 2012 Apr 10; 29(6):1156-66.
-
Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer. 2011 Aug 15; 117(16):3641-9.
-
Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats. J Pharmacol Exp Ther. 2011 May; 337(2):451-6.
-
Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice. Pediatr Res. 2011 Jan; 69(1):56-61.
-
Combination of deferoxamine and erythropoietin: therapy for hypoxia-ischemia-induced brain injury in the neonatal rat? Neurosci Lett. 2009 Feb 20; 451(2):109-13.
-
Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer. 2008 Sep 15; 113(6):1480-8.
-
Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev. 2008 Nov; 59(1):22-33.
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27; 299(8):914-24.
-
Extramedullary erythropoiesis in chronic subdural hematoma simulating metastatic small round cell tumor. Int J Surg Pathol. 2007 Jul; 15(3):288-91.